Why Is INHIBRX BIOSCIENCES (INBX) Stock Down Today?

INBX stock rose 5.36% to $107.16 on Thursday, driven by a combination of insider buying activity and updated corporate disclosures. The stock opened with a 3.5% gap up from the prior close and continued to climb through the morning session. Recent developments including a new investor presentation and a CEO equity purchase have drawn attention to the company.

What Happened

The stock’s upward movement was fueled by the announcement that Inhibrx Biosciences CEO Mark Lappe exercised an option and purchased $998.8K in common stock on September 25. This was followed by the company filing a Form 8-K on September 28, disclosing updated corporate materials and financial information. Inhibrx also released a revised investor presentation outlining its pipeline and corporate strategy. These actions suggest a renewed focus on transparency and long-term value creation. Additionally, the company is preparing to expand its clinical trial for head and neck cancer following high response rates reported in prior trials, as noted in recent news from Benzinga.

What The Data Shows

The stock opened at $105.31 and reached a high of $107.90 before settling at $107.16. The session volume remains at 0.0M shares, which is 0.0x the 3-month average. Over the past 8 sessions, the stock had declined 2.4% from $106.33 to $103.82. Insider activity has been positive in recent months, with six buys totaling $5.5M reported in the last 90 days. The stock also printed two fresh 52-week highs on September 29, indicating strong retail and institutional interest.

What To Watch

The company is scheduled to present Phase 2 results for INBRX-106 in head and neck squamous cell carcinoma on a webcast on September 8. Coverage breadth and investor reaction to that presentation will be key to monitoring the stock’s trajectory.